Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.
Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T. Kammertoens T, et al. Among authors: leisegang m. Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26. Nature. 2017. PMID: 28445461 Free PMC article.
Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors.
Schreiber K, Karrison TG, Wolf SP, Kiyotani K, Steiner M, Littmann ER, Pamer EG, Kammertoens T, Schreiber H, Leisegang M. Schreiber K, et al. Among authors: leisegang m. Cancer Immunol Res. 2020 Feb;8(2):192-202. doi: 10.1158/2326-6066.CIR-19-0567. Epub 2019 Dec 12. Cancer Immunol Res. 2020. PMID: 31831634 Free PMC article.
Designer T cells by T cell receptor replacement.
Sommermeyer D, Neudorfer J, Weinhold M, Leisegang M, Engels B, Noessner E, Heemskerk MH, Charo J, Schendel DJ, Blankenstein T, Bernhard H, Uckert W. Sommermeyer D, et al. Among authors: leisegang m. Eur J Immunol. 2006 Nov;36(11):3052-9. doi: 10.1002/eji.200636539. Eur J Immunol. 2006. PMID: 17051621 Free article.
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R, Olguín-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Rühland S, Nelson PJ, Leonhardt H, Harz H, Wilde S, Schendel DJ, Uckert W, Willimsky G, Noessner E. Schlenker R, et al. Among authors: leisegang m. Cancer Res. 2017 Jul 1;77(13):3577-3590. doi: 10.1158/0008-5472.CAN-16-1922. Epub 2017 May 22. Cancer Res. 2017. PMID: 28533272
Targeting cancer-specific mutations by T cell receptor gene therapy.
Blankenstein T, Leisegang M, Uckert W, Schreiber H. Blankenstein T, et al. Among authors: leisegang m. Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Curr Opin Immunol. 2015. PMID: 25728991 Free PMC article. Review.
100 results